Multimodal Augmented Reality for Operative Guidance in Interventional Neuroradiology

Submission date 14/08/2024	Recruitment status Recruiting	Prospectively registered
		☐ Protocol
Registration date 03/09/2024	Overall study status Deferred	Statistical analysis plan
		☐ Results
Last Edited	Condition category	Individual participant data
16/05/2025	Other	[X] Record updated in last year

Plain English summary of protocol

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Contact information

Type(s)

Principal investigator

Contact name

Prof Kyriakos Lobotesis

ORCID ID

https://orcid.org/0000-0001-5093-9751

Contact details

Imperial College Healthcare NHS Trust Charing Cross Hospital Fulham Palace Road London United Kingdom **W6 8RF**

k.lobotesis@nhs.net

Type(s)

Public, Scientific

Contact name

Dr Philip Pratt

Contact details

Medical iSight (UK) Ltd 9th Floor 107 Cheapside London United Kingdom EC2V 6DN

_

pjp@medicalisight.com

Additional identifiers

Clinical Trials Information System (CTIS)

Nil known

Integrated Research Application System (IRAS)

319189

ClinicalTrials.gov (NCT)

Nil known

Protocol serial number

CPMS 54208

Study information

Scientific Title

Multimodal Augmented Reality for Operative Guidance in Interventional Neuroradiology

Acronym

MAROG-INR

Study objectives

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Ethics approval required

Ethics approval required

Ethics approval(s)

approved 21/02/2023, London - Dulwich Research Ethics Committee (Skipton House, 80 London Road, London, SE1 6LH, United Kingdom; +44 (0)207 104 8290; dulwich.rec@hra.nhs.uk), ref: 23 /LO/0030

Study design

Single-centre interventional trial in patients undergoing interventional neuroradiology procedures

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Interventions

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Intervention Type

Other

Primary outcome(s)

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Key secondary outcome(s))

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Completion date

01/07/2026

Eligibility

Key inclusion criteria

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

All

Key exclusion criteria

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Date of first enrolment 01/09/2024

Date of final enrolment 01/04/2026

Locations

Countries of recruitment United Kingdom

England

Study participating centre Charing Cross Hospital Fulham Palace Road London United Kingdom W6 8RF

Sponsor information

Organisation

Medical iSight (UK) Limited

Funder(s)

Funder type

Other

Funder Name

Self-funded

Results and Publications

Individual participant data (IPD) sharing plan

The datasets generated and/or analysed during the current study are not expected to be made available because of their high commercial sensitivity and the negligible benefit to the public of publication of results of non-therapeutic clinical trials.

IPD sharing plan summary

Not expected to be made available

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?

Participant information sheet 11/11/2025 No Yes